---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-287170"
form_type: "8-K"
ticker: "TPST"
cik: "0001544227"
company_name: "Tempest Therapeutics, Inc."
filed_at: "2024-12-31T23:59:59+00:00"
generated_at: "2026-05-28T21:40:25.814467+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Tempest Therapeutics receives Nasdaq bid price deficiency notice; stock below $1.00

## Summary
- Received Nasdaq deficiency letter on Dec 27, 2024 for bid price below $1.00 for 30 consecutive business days.
- Has 180 calendar days (until June 25, 2025) to regain compliance by closing at $1.00+ for 10 consecutive days.
- Stockholders approved a reverse stock split (range 1:2 to 1:15) on Dec 3, 2024; Board may implement to cure deficiency.
- If not compliant by June 25, 2025, may qualify for an additional 180-day period if other listing standards are met.

## SEC filing metadata
- accession: 0001193125-24-287170
- form_type: 8-K
- ticker: TPST
- cik: 0001544227
- company_name: Tempest Therapeutics, Inc.
- filed_at: 2024-12-31T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1544227/000119312524287170/0001193125-24-287170-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1544227/000119312524287170/d848354d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-287170
- JSON: https://secwatch.observer/filing/0001193125-24-287170.json
- Plain text: https://secwatch.observer/filing/0001193125-24-287170.txt

## Key facts
- Listing & Compliance Notices
  Tempest Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2), 5810(c)(3)(A)
  source text: December 27, 2024, Tempest Therapeutics, Inc., a Delaware corporation (the “Company”), received a letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the last 30 consecutive business days, the bid price of the Company’s common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq Listing Rule 5550(a)(2). The notification received has no immediate effect on the listing of the Company’s common stock on the Nasdaq Stock Market. In accordance with
  evidence_url: https://www.sec.gov/Archives/edgar/data/1544227/000119312524287170/0001193125-24-287170-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.